Document is current
Any future updates will be listed below
-
Authors
Luo, Jie
Chen, Zhixiang https://orcid.org/0009-0007-4526-1588
Qiao, Yuanyuan https://orcid.org/0000-0002-1178-3480
Tien, Jean Ching-Yi
Young, Eleanor https://orcid.org/0000-0001-5393-530X
Mannan, Rahul https://orcid.org/0000-0002-6642-0468
Mahapatra, Somnath https://orcid.org/0000-0001-9490-6353
Bhattacharyya, Rupam
Xiao, Lanbo
He, Tongchen
Eyunni, Sanjana
Zhang, Yuping
Zheng, Yang https://orcid.org/0000-0002-6793-3206
Su, Fengyun
Cao, Xuhong
Wang, Rui https://orcid.org/0000-0002-5356-9685
Cheng, Yunhui
Seri, Rithvik
George, James https://orcid.org/0000-0002-9723-6444
Shahine, Miriam
Miner, Stephanie J. https://orcid.org/0009-0005-6680-900X
Rees, Matthew G. https://orcid.org/0000-0002-2987-7581
Ronan, Melissa M. https://orcid.org/0000-0003-4269-1404
Roth, Jennifer A. https://orcid.org/0000-0002-5117-5586
Vaishampayan, Ulka
Wang, Mi
Wang, Shaomeng https://orcid.org/0000-0002-8782-6950
Parolia, Abhijit
Chinnaiyan, Arul M. https://orcid.org/0000-0001-9282-3415
-
Funding
Funding for this research was provided by:
Prostate Cancer Foundation (Challenge Award, Young Investigator Award, Challenge Award, Challenge Award, Challenge Award, Young Investigator Award)
U.S. Department of Health & Human Services | NIH | National Cancer Institute (P50-CA186786, R35-CA231996, U2C-CA271854)
U.S. Department of Health & Human Services | National Institutes of Health (R01CA289013, 5 K00 CA245825)
University of Michigan (Rogel Fellow Award)
- License Information
-
More Information
Article History
Received: 20 November 2024
Accepted: 18 August 2025
First Online: 3 October 2025
Competing interests
: S.W. was a co-founder and served as a paid consultant to Oncopia Therapeutics. S.W. and the University of Michigan owned equity in Oncopia Therapeutics, which was acquired by Roivant Sciences and Proteovant Therapeutics. S.W. is a paid consultant to Proteovant Therapeutics. The University of Michigan has received a research contract from Oncopia Therapeutics, for which S.W. serves as the principal investigator. A.M.C. is a co-founder and serves on the scientific advisory board of Lynx Dx, Oncopia Therapeutics, Flamingo Therapeutics, Medsyn Pharma and Esanik Therapeutics. A.M.C. serves as an advisor to Tempus, Aurigene Oncology, Proteovant and Ascentage. The other authors declare no competing interests. The authors have filed patents on (1) orally active p300/CBP degraders (US patent application no. 63/563,534) and (2) elevation of H2NTac in prostate cancer.
